



Houston's early-stage life science commercialization platform

Defining a Novel Approach to Life Sciences Commercialization

August 2024

Active Development Programs



Pulmotect's lead product, Pul-042, is a clinical-stage inhaled therapeutic that stimulates innate immune system to prevent infection.*



Procyrion is in Phase 2 clinical testing of Aortix, a minimally invasive ambulatory device for treating the 2 million heart failure patients too sick for medication.*



BreviTest is developing a rapid point-of-care diagnostic platform for sensitive and quantitative detection of analytes.



Raptamer Discovery Group is developing targeted drug conjugates and radiopharmaceuticals based on Raptamers™, a novel theranostic modality that incorporates advances in oligonucleotide and peptide therapeutics. Our most advanced Raptamer Drug Conjugate (RapDC™) targeting an attractive first-in-class oncology target has demonstrated in-vivo proof of concept. Radioligand therapies (Radiomers™) against established and novel targets are in preclinical testing.



Fannin has several programs whose licensing is underway.



Allterum is developing an IL-7R antibody for the treatment of pediatric T-Cell Acute Lymphoblastic Leukemia.



Radiomer Therapeutics is developing targeted radiopharmaceutical agents against established and first-on-class oncology targets.




Brimstalt is developing a targeted chemotherapy for cancer.



Goldenrod is developing a small molecule to prevent pathogenic activity in a variety of immune cells, including those that contribute to neurodegeneration.

Our Pipeline



* Independent Fannin Established Company

Fannin – In a Nutshell

An integrated approach to life sciences and human capital development



Academic Researchers



IP, Research/Clinical Collaborators
NOT part of management team



Experienced, Pooled
Team



Address CEO Bottleneck



Interns and Product
Development Associates



Amplify Team
Train Emerging Entrepreneurs



Smart Funding



Risk- and Stage-Optimized \$\$\$

“My primary responsibility at MD Anderson is to support innovation by assisting our faculty who are pursuing the commercialization their research. Fannin plays an important role in this process, working closely with some of our researchers and clinicians to advance development and spin out companies, while providing opportunities for life sciences entrepreneurs to train and grow. I enjoy working with the Fannin team and I appreciate the critical role they play in our local ecosystem.”

- Chris Taylor

Director, Office of Career & Entrepreneurship Advancement, University of
Texas MD Anderson Cancer Center

Our Inventors and Collaborators



Roberto Adachi, MD
Associate Professor
Pulmonary Medicine
MD Anderson Cancer Center



Michael Belfort, MD, PhD
Professor & Chair
Dept of OB/GYN
Baylor College of Medicine



Achu Byju, PhD
Research Associate II
Biomedical Engineering
Texas A&M University



Roy F. Chemaly, MD, MPH
Professor
Infectious Diseases
MD Anderson Cancer Center



Seong H. Cho, MD
Associate Professor
Allergy and Immunology
University of South Florida



William E. Cohn MD, FACS, FACCP, FAHA
Director
Center for Technology Innovation
Texas Heart Institute



David Corry, MD
Professor
Immunology, Allergy & Rheumatology
Baylor College of Medicine



Reynolds M. Delgado III, MD, FACC
Medical Director
Mechanical Assist Devices
Texas Heart Institute



Burton Dickey, MD
Professor & Chair
Pulmonary Medicine
MD Anderson Cancer Center



Scott K. Durum, PhD
Senior Investigator
Cancer & Inflammation Program
National Cancer Institute



Jimmy Espinoza, MD
Co-Director
OB/GYN & Fetal Center
Texas Children's Hospital



Scott E. Evans, MD, FCCP
Professor
Pulmonary Medicine
MD Anderson Cancer Center



David Gorenstein, PhD
President and Founder
AptaMed, Inc.



Balakrishna Haridas, PhD
Senior Director
Front End Innovation
Ethicon Inc., J&J Medical Devices



Magnus Höök, PhD
Regent Professor & Director
Infectious & Inflammatory Diseases
Texas A&M University



Corey Hopkins, PhD
Associate Professor
Pharmaceutical Sciences
University of Nebraska



Sebastian Johnston
Professor
Respiratory Medicine & Allergy
Imperial College London



John Morgan Knight, PhD
Instructor
Immunology, Allergy & Rheumatology
Baylor College of Medicine



Chester Koh, MD
Professor
Urology, Pediatrics, and OB/GYN
Texas Children's Hospital



Andras Lacko, PhD
Professor
Physiology & Anatomy
University of North Texas



Duncan Maitland, PhD
Professor
Biomedical Engineering
Texas A&M University



Kanwal Raghav, MBBS, MD
Associate Professor
Genitourinary Medical Oncology
MD Anderson Cancer Center



Eric S. Schafer, MD, MHS
Assistant Professor
Pediatrics-Oncology
Texas Children's Hospital



Ajay Sheshadri, MD
Assistant Professor
Pulmonary Medicine
MD Anderson Cancer Center



Anil K. Sood, MD
Professor & Vice Chairman
Gyn. Oncology & Rep. Med
MD Anderson Cancer Center



Kara Toman, MPH
Senior Research Director
Pediatric Urology
Texas Children's Hospital



Michael Tuvim, PhD
Professor
Pulmonary Medicine
MD Anderson Cancer Center



Sara J. Ward, PhD
Assistant Professor
Pharmacology
Temple University



“As the world’s leading cancer hospital, the research and clinical faculty at MD Anderson generates a remarkable breadth of basic sciences and clinical insights. Fannin provides unique approach to partnering with academic researchers to advance innovation, with the goal of helping shape the future of patient care.”

Ronald A. DePinho, MD -
Former President of MD Anderson Cancer Center



Core Fannin Team & Portfolio Leadership

Our Core Team



Team Attributes:

- Experience in drug and device development
- Medical/Scientific/Engineering background
- Interest in life sciences entrepreneurship
- Business/project management experience
- Strong history of leadership

Procyron



Eric Fain, MD
President & CEO, Procyron



Jason Heuring, PhD
COO, Procyron



Av Edidin, PhD
Sr. VP, Development & Manufacturing



PULMOTECT



Colin Broom, BSc, MB BS, MRCP, FFPM
CEO, Pulmotect



Brenton Scott, PhD, MBA
President, Pulmotect




John Schaumberg, PhD
Clinical Operations, Pulmotect

Fannin's Talent Development Program



- Targets early-career scientists, physicians, and engineers with product development interest, including 8,000+ in Houston
- Provides direct development experience across a broad range of life sciences programs.
- Part-time Internships and full-time Product Development Associate (formerly "Fellowship").
- Over 320 alumni who have gone on to multiple roles in Houston and beyond.



Diversified and Disciplined Program Funding

\$245M

Investment Across Programs

\$73M Grants		\$172M Investors	
\$27M SBIR/STTR ¹	\$46M Other ²	\$22M Fannin Platform ³	\$150M Spun-out Programs ⁴

¹ NIH (NHLBI, NIAID, NIDA, NIA, NIDDK, NICHD, NCATS) and NSF.

² CPRIT, NIH, DOD, NASA, and Philanthropic Foundations.

³ Three equity investment rounds in Fannin Partners.

⁴ 16 equity rounds in spun-out portfolio companies.

"Fannin's impact is reflected in their being awarded a Tibbetts Award that exemplifies the very best in SBIR/STTR achievements. We are delighted that Fannin has been actively engaged with the SBA in so many ways and we wish them the very best."

- **Tim Jeffcoat**

Director, US Small Business⁸ Administration – Houston District Office



Creating Value for Early-Stage Technologies



Contact Info:



Michael J. Heffernan, PhD

Director, Research & Technology

michael@fannininnovation.com

[linkedin.com/in/mjheffernan](https://www.linkedin.com/in/mjheffernan)



www.fannininnovation.com



[Fannin Innovation](https://www.linkedin.com/company/fannin-innovation)

